OLMA
OLMA
$7.11
+8.05% 2026-10-19
Sector n/a
OLMASPY
1W
-3.4%
1M
-27.6%
3M
-37.4%
6M
-57.1%
YTD
-71.6%
1Y
-24.0%
Grades vs sector
Momentumno data–
Momentum
no data
Percentile within its GICS sector across the S&P 1500.
Growthno data–
Growth
no data
Percentile within its GICS sector across the S&P 1500.
Valueno data–
Value
no data
Percentile within its GICS sector across the S&P 1500.
Profitabilityno data–
Profitability
no data
Percentile within its GICS sector across the S&P 1500.
Revisionsno data–
Revisions
no data
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 3 live models right now.
Momentum Top 15
not ranked (outside this model's universe or screens)
Quality Growthnot ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
Key stats
Market cap–
P/E (trailing)–
P/E (forward)–
52-week range– – –
Revenue growth (YoY, latest qtr)–
Dividend yield–
Analyst consensus–
Mean price target–
Valuation & fundamentals
No US-GAAP 10-K/10-Q financials in SEC data (foreign filers report on Form 20-F, often under IFRS).
Earnings
Next report: 2026-11-09 · during market · EPS est -0.63
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-10 | -0.56 | -0.61 | -8.2% |
| 2026-05-12 | -0.54 | -0.52 | +3.5% |
| 2026-03-16 | -0.53 | -0.50 | +5.1% |
| 2025-11-10 | -0.45 | -0.49 | -8.5% |
| 2025-08-11 | -0.44 | -0.51 | -17.1% |
| 2025-05-13 | -0.46 | -0.36 | +22.3% |
| 2025-03-18 | 0.17 | -0.51 | -394.5% |
| 2024-11-12 | -0.57 | -0.60 | -5.0% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $0 | – |
| 2026-03-31 | $0 | – |
| 2025-12-31 | $0 | – |
| 2025-09-30 | $0 | – |
| 2025-06-30 | $0 | – |
Insider trades
Harmon Cyrus
$146.4K
Director · 2026-07-24
SELL$146.4K
Harmon Cyrus
$144.7K
Director · 2026-07-23
SELL$144.7K
None
–
None · None
SELL–
News
The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema Oncology
Zacks · 22h ago
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
Zacks · Oct 16
SERD Market Set for Growth During the Forecast Period (2026-2036) as AstraZeneca's ETCAMAH Approval Accelerates Adoption of Oral SERDs | DelveInsight
PR Newswire · Oct 05
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Oct 02
Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results
InvestorsHub · Sep 14
Top Premarket Decliners
MT Newswires · Sep 14
Premarket movers: AI stocks slide on warnings, Rumble, Scholar Rock jump
Investing.com · Sep 14
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 02
Stats refreshed 2026-10-19 19:02:56 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic StrategiesSystematic equity research and model portfolios.Coteau Systematic Strategies publishes research, model portfolios and tools. It does not manage money or offer investment advice. Model results are hypothetical. Data: Yahoo Finance (delayed), SEC EDGAR.